Abstract：
OBJECTIVES:To compare the liver safety profile of interferon β (IFN β) and teriflunomide in patients with multiple sclerosis. METHODS:A network meta-analysis was carried out following the Cochrane Collaboration methodology. All trials comparing all types of IFN β with teriflunomide, or disease-modifying drugs, or placebo in RRMS were included. An indirect comparison network meta-analysis within a Bayesian framework with STATA (version 13.0) was done for this study. RESULTS:The database searches yielded 284 titles, with 15 records as duplicates. One study was identified by manually searching. Thirteen articles were included in the systematic review. Twelve studies compared IFN β (4203 patients) vs another DMT. Four studies evaluated the effectiveness and safety of teriflunomide (906 patients) vs another DMT. Six studies reported drug-induced liver injury as per the Hy's Law. However, only one study had a direct comparison and reported no cases of liver toxicity in either group, so it was not possible to estimate the OR. The indirect comparisons metanalysis shows that there was no statistically-significant difference between teriflunomide and IFN β (OR 1.09, 95% CI 0.02-2.16). CONCLUSIONS:There were no significant difference when comparing IFN β and teriflunomide in terms of liver failure or elevation of transaminases.
journal_name
Mult Scler Relat Disordjournal_title
Multiple sclerosis and related disordersauthors
Salas PAO,Parra CO,Florez CEP,Goez LM,Velez-van-Meerbeke A,Rodriguez JHdoi
10.1016/j.msard.2018.09.014subject
Has Abstractpub_date
2018-11-01 00:00:00pages
192-200eissn
2211-0348issn
2211-0356pii
S2211-0348(18)30326-2journal_volume
26pub_type
杂志文章,meta分析abstract：BACKGROUND:As vaccines for the coronavirus become available, it will be important to know the rate of COVID-19 vaccine acceptability in adults with multiple sclerosis (MS), given that vaccination will be a key strategy for preventing SARS-CoV-2 infections. Using a national sample of adults with MS in the United States ...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2021.102788
更新日期：2021-01-22 00:00:00
abstract：BACKGROUND:It has been suggested that comorbidity in subjects with multiple sclerosis (MS) increases the risk of hospitalizations, although few studies have examined this, and rarely in an incident population. METHODS:Incident MS cases were identified retrospectively from administrative data in Saskatchewan, Canada (1...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.101955
更新日期：2020-05-01 00:00:00
abstract：BACKGROUND:Anti-CD20 monoclonal antibodies such as ocrelizumab, rituximab, and ofatumumab target B-cell lineage. Clinical trials have demonstrated their effect on reducing both magnetic resonance imaging (MRI) active lesion burden as well as clinical activity. Zytux™ (Rituximab, AryoGen Pharmed) used in the present stu...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.101419
更新日期：2019-11-01 00:00:00
abstract：BACKGROUND:MS imposes a significant burden on patients, caregivers, employers, and the healthcare system. OBJECTIVE:To comprehensively evaluate the US MS burden using nationally representative data from the Medical Expenditure Panel Survey. METHODS:We identified non-institutionalized patients aged ≥18 with MS (ICD-9 ...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2013.09.004
更新日期：2014-03-01 00:00:00
abstract：:Iatrogenic demyelination is a distinct clinical subtype of central nervous system inflammatory disorders. The Janus kinase inhibitor, tofacitinib, is an oral disease-modifying antirheumatic drug that has shown contradictory effects on multiple sclerosis in animal models. In this report, we describe a novel case of rev...
journal_title：Multiple sclerosis and related disorders
pub_type： 信件
doi：10.1016/j.msard.2020.102568
更新日期：2020-11-01 00:00:00
abstract：BACKGROUND:There are limited data on the impact of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on people with multiple sclerosis (MS). OBJECTIVE:To better understand SARS-CoV-2 infection in ocrelizumab-treated people with MS. METHODS:Internal Roche/Ge...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102725
更新日期：2020-12-30 00:00:00
abstract：BACKGROUND:Daytime sleepiness is a common symptom of multiple sclerosis (MS) that may jeopardize safe driving. Our aim was to compare daytime sleepiness, recorded in real-time through eyelid tracking, in a simulated drive between individuals with MS (iwMS) and healthy controls. METHODS:Fifteen iwMS (age = median (Q1 -...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102607
更新日期：2020-10-31 00:00:00
abstract：BACKGROUND:In 2001, we conducted a survey on use of complementary and alternative medicine (CAM) in people with multiple sclerosis (pwMS) in Oregon and Southwest Washington to treat their disease. OBJECTIVES, METHODS:In 2018, we administered a revised survey in the same region to describe updated patterns of CAM use i...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102041
更新日期：2020-06-01 00:00:00
abstract：:Randomized placebo-controlled clinical trials have been considered the most rigorous method of evaluating the efficacy of novel treatment interventions. The first effective disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) were approved in the 1990s after a number of pivotal placebo-...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章,评审
doi：10.1016/j.msard.2016.03.019
更新日期：2016-05-01 00:00:00
abstract：BACKGROUND:Considering the multiple treatments approved for multiple sclerosis (MS) by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), determining a treatment strategy for patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) can be challenging. To date, an overv...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章,评审
doi：10.1016/j.msard.2020.101929
更新日期：2020-01-02 00:00:00
abstract：BACKGROUND:Underestimation of relapse in multiple sclerosis (MS) is detrimental to the patient as well as to their relationship with their MS healthcare professional (HCP). OBJECTIVE:To obtain direct insight into relapse prevalence, symptoms, and HCP engagement from patients with MS who responded to the Multiple Scler...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2018.09.002
更新日期：2018-11-01 00:00:00
abstract：:Fingolimod, taken orally once per day, is approved for the treatment of relapsing-remitting multiple sclerosis (MS). It should be stopped at least two months before conception as it is not considered safe during pregnancy or when breast feeding. In vitro and animal studies have found a possibly increased risk of conge...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2018.02.015
更新日期：2018-04-01 00:00:00
abstract：:Falls in people with Multiple Sclerosis (PwMS) is a serious issue. It can lead to a lot of problems including sustaining injuries, losing consciousness and hospitalization. Having a model that can predict the probability of these falls and the factors correlated with them and can help caregivers and family members to ...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2021.102740
更新日期：2021-01-07 00:00:00
abstract：:The identification of AQP4-IgG, a specific and pathogenic antibody of NMO/SD has led to a broadening of the clinical spectrum of manifestations of NMO/SD including the presence of encephalic symptoms. Lesions are often distributed on peri‑ependymal area and sometimes affected the diencephalon leading to sleep disorder...
journal_title：Multiple sclerosis and related disorders
pub_type：
doi：10.1016/j.msard.2019.101869
更新日期：2020-02-01 00:00:00
abstract：BACKGROUND:Little is known about the factors associated with the selection of Disease Modifying Agents (DMA) for the management of Multiple Sclerosis (MS) since the introduction of oral DMAs in 2010. OBJECTIVES:To examine the factors associated with initiation of oral DMAs in patients with MS using data from electroni...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102334
更新日期：2020-10-01 00:00:00
abstract：:Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disorder characterised by psychiatric symptoms, movement disorder and seizures often evolving into a severe encephalopathy. An overlap has recently been recognised between anti-NMDAR encephalitis and inflammatory demyelinating disorders, particul...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2016.12.009
更新日期：2017-02-01 00:00:00
abstract：:We present a 26 year old Pakistani lady with first presentation of a demyelinating event, presenting as Parinaud's syndrome. The video demonstrates a convergence-retraction nystagmus on upgaze and failure of accommodation, and her brain imaging confirms a corresponding pre-tectal contrast enhancing T2 hyperintense les...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2013.09.003
更新日期：2014-05-01 00:00:00
abstract：BACKGROUND:Cognitive impairment and psychiatric symptoms impact many aspects of the lives of people with multiple sclerosis [MS]. This literature is based largely on North American and Western European samples, and little is known about these aspects of MS disability in Latin America. OBJECTIVE:RELACCEM is a longitudi...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2013.10.007
更新日期：2014-05-01 00:00:00
abstract：BACKGROUND:Notoriously the treatment of multiple sclerosis (MS) is based on the use of several different drugs, characterized by a diverse mechanism of action, efficacy and safety. Recently, progress has been made towards developing new oral immunotherapies, and dimethyl fumarate is the third oral agent approved for th...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2016.03.009
更新日期：2016-05-01 00:00:00
abstract：:Rituximab is a chimeric anti-CD20 monoclonal antibody that is an effective therapy for multiple sclerosis. Rituximab has been associated with the development of serum sickness (type III hypersensitivity) characterized by arthralgia, fever, and rash during the treatment of other conditions, such as rheumatoid arthritis...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.101402
更新日期：2019-11-01 00:00:00
abstract：:Multiple sclerosis (MS) is a chronic disease characterized by inflammation, demyelination and neurodegeneration in the central nervous system. Recent studies suggested that patients with MS might have a greater risk of ischaemic stroke (IS). IS treatment with intravenous alteplase (IVA) in MS has rarely been reported....
journal_title：Multiple sclerosis and related disorders
pub_type：
doi：10.1016/j.msard.2020.101962
更新日期：2020-05-01 00:00:00
abstract：BACKGROUND:Delayed multiple sclerosis (MS) diagnoses are not uncommon, an early diagnostic tool is urgently warranted. We aimed to develop an effective tool through electronic health records and machine learning techniques to early recognize MS patients from hospital visitors in China. METHODS:Two case sets were colle...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102632
更新日期：2020-11-18 00:00:00
abstract：OBJECTIVE:To examine whether cognitive and physical fatigue are differentially associated with problems in self-care, mobility, relationships, participation, psychological well-being, and quality of life in people with multiple sclerosis. METHODS:A cross-sectional study involving seventy-four community-dwelling people...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.03.024
更新日期：2019-06-01 00:00:00
abstract：BACKGROUND:Cognitive impairment is highly prevalent in multiple sclerosis (MS). Due to the lack of specialized neuropsychological resources in many MS clinics, a brief cognitive monitoring tool that can be administered by other MS clinic staff is needed. BICAMS (Brief International Cognitive As-sessment for Multiple Sc...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.101458
更新日期：2020-01-01 00:00:00
abstract：BACKGROUND:Disturbances that occur in patients with multiple sclerosis (MS) are not restricted to motor, sensory, or urinary functions; they also include cognitive dysfunction, fatigue, and depression. Moreover, people with MS are known to have fewer social activities and a reduced quality of life. One aspect of social...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2014.02.001
更新日期：2014-07-01 00:00:00
abstract：BACKGROUND:Multiple sclerosis (MS) is an inflammatory autoimmune neurologic disease that causes progressive destruction of myelin sheath and axons. Affecting more than 2 million people worldwide, MS may presents distinct clinical courses. However, information regarding key gene expression and genic pathways related to ...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102243
更新日期：2020-09-01 00:00:00
abstract：BACKGROUND:Neuromyelitis optica spectrum disorder (NMOSD) is a complex disease characterized by a severe inflammation of the central nervous system (CNS). This disease typically manifests with recurrent optic neuritis (ON) and acute transverse myelitis (ATM). The clinical and radiological spectrum of NMOSD is little kn...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102208
更新日期：2020-09-01 00:00:00
abstract：OBJECTIVES:To examine the association between vagotomy and multiple sclerosis. METHODS:We conducted a matched cohort study of all patients who underwent truncal or super-selective vagotomy and a comparison cohort, by linking Danish population-based medical registries (1977-1995). Hazard ratios (HRs) for multiple scler...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2017.04.009
更新日期：2017-07-01 00:00:00
abstract：BACKGROUND:Leptomeningeal inflammation is associated with increased cortical damage and worse clinical outcomes in MS. It may be detected on contrast-enhanced T2-FLAIR imaging as focal leptomeningeal contrast-enhancement (LME). OBJECTIVE:To assess the safety of intrathecal (IT) rituximab in progressive MS (PMS) and to...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.02.013
更新日期：2019-05-01 00:00:00
abstract：BACKGROUND:Multiple Sclerosis (MS) is a degenerative disease of central nervous system caused by an immune response against the myelin. About half of MS patients suffers from sleep disturbances. The circadian clock genes such as PER3 controls circadian rhythm and sleep. Due to the role of PER3 in sleep disturbances and...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2017.07.005
更新日期：2017-10-01 00:00:00
